External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology ESMO Asia 2024
Roche and Genentech at

ESMO Asia 2024

December 06 - December 08
Singapore, Republic of Singapore
www.esmo.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Dec 7 / Roche and Genentech
Whole exome sequencing (WES) analyses from IMpower133 and 6-year (y) overall survival (OS) from IMbrella A in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with atezolizumab (atezo)
The Phase III IMbrella A study (NCT03148418; single-arm extension of IMpower133 [NCT02763579]) provided the first report of exploratory 5-year OS rate for 1L cancer immunotherapy (atezolizumab in combination with carboplatin plus etoposide) in patients with ES-SCLC. This poster reports exploratory analyses of the updated time-to-event data from patients who rolled over to IMbrella A, alongside the association of whole exome sequencing genomic alterations with OS in patients who were enrolled in IMpower133.
Oncology Lung Cancer ESMO-ASIA-2024

Sign up or login to unlock the full suite of MEDICALLY features
Dec 7 / Roche and Genentech
Resistance mechanisms and efficacy of first-line (1L) alectinib in patients with ALK-rearranged non-small cell lung cancer: second interim analysis of ALCURE
Second interim analysis from the real-world ALCURE study exploring resistance mechanisms to first-line alectinib, prognostic factors of the efficacy of alectinib and optimal treatment sequences in Japanese patients with advanced ALK+ NSCLC.
Oncology Lung Cancer ESMO-ASIA-2024

Sign up or login to unlock the full suite of MEDICALLY features
Dec 7 / Roche and Genentech
SKYSCRAPER-02C: phase 3 study of atezolizumab + carboplatin + etoposide (CE) with or without tiragolumab in patients with untreated extensive-stage small cell lung cancer (ES-SCLC) in China
Efficacy and safety of atezolizumab + carboplatin + etoposide with or without tiragolumab in patients with untreated extensive-stage small cell lung cancer in China from the phase 3 SKYSCRAPER-02C study.
Oncology Lung Cancer ESMO-ASIA-2024
04:00 AM
Duration 90mins Singapore, Republic of Singapore
Patient-centricity in Action: Innovating for Today and the Future in Lung and Liver Cancers
Prof. Toh Han Chong (Chair), Dr. David James Pinato, Prof. Sun Hui-Chuan, Assoc. Prof. Krittiya Korphaisarn, Mr. Eric Liu
Oncology | Hepatocellular Carcinoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:15 AM
Duration 5mins Hall 406
ALESIA 7-year update: alectinib vs crizotinib in Asian patients with treatment-naïve advanced ALK+ non-small cell lung cancer
Zhou C, Lu Y, Kim S-W, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang J-J, Cheng Y, Lee S-H, Chang J, Fang J, Liu Z, Bu L, Qian L, Archer V, Zhou M, Zhang L
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:50 AM
Duration 55mins Singapore, Republic of Singapore
Whole exome sequencing (WES) analyses from IMpower133 and 6-year (y) overall survival (OS) from IMbrella A in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with atezolizumab (atezo)
Steven Kao, Martin Reck, Stephen V. Liu, Rafal Dziadziuszko, Maximilian Hochmair, Florian Huemer, Gilberto Castro, Junior, Reyes Bernab Caro, Se Hyun Kim, Dariusz Kowalski, Zoran Andric, Marcela Oancea, Monika Kaul, Huafei Li, Bradford Danner, Myung Chang Lee, Barzin Nabet, Shunichi Sugawara
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 55mins Singapore, Republic of Singapore
Patient satisfaction and preference for atezolizumab subcutaneous by body mass index (BMI) or race (Asian vs non-Asian) from IMscin001 and IMscin002
Chewaskulyong B, Zvirbule Z, Lee KH, Yovanna Castro Sanchez A, Bustillos A, Herraez-Baranda L, Liu LX, Kim S-W
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 55mins Singapore, Republic of Singapore
Resistance mechanisms and efficacy of first-line (1L) alectinib in patients with ALK-rearranged non-small cell lung cancer: second interim analysis of ALCURE
Atsuto Mouri, Takeshi Tsuda, Masahide Oki, Eiki Ichihara, Hiroshi Tanaka, Koichi Azuma, Ryo Arai, Shoichi Kuyama, Hiroaki Akamatsu, Kohei Otsubo, Hitomi Ajimizu, Marie Matsumoto, Yosuke Seto, Ken Uchibori, Hidetoshi Hayashi, Eisaku Miyauchi, Naoki Ishizuka, Yusuke Kajihara, Yuki Nakagawa, Ryohei Katayama
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 55mins Singapore, Republic of Singapore
SKYSCRAPER-02C: phase 3 study of atezolizumab + carboplatin + etoposide (CE) with or without tiragolumab in patients with untreated extensive-stage small cell lung cancer (ES-SCLC) in China
Shun Lu, Jian Fang, Yan Yu, Yun Fan, Xiaorong Dong, Haiyan Wang, Chanjuan Lin, Li Zhang, Raymond Meng
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.